Results of thrombolytic treatment with recombinant streptokinase in elderly and non elderly patients. Resultados del tratamiento trombolítico con estreptoquinasa recombinante en pacientes ancianos y no ancianos.

Fundament: The great advances of modern medicine in the last 30 years, have deepened on the treatment of acute myocardial infarct dynamically and efficiently, allowing at present to show good results not only in the decrease of the mortality rate but also in the improvement of the patienta?Ts quality of life. Objective: To offer the precise results with recombinant sterptokinase in elder and non-elder patients with an acute myocardial infarct. Method: prospective observational study of 325 patients admitted with a diagnosis of an acute myocardial infarct at the ¨Dr. Gustavo Aldereguia Lima¨ Hospital. These patients received thrombolitic treatment with recombinant strptokinase (Heberkinase) i a dose of 1 500 000 units, and treatment with 325 mg of acetil salicilic acid too. Results: The presence of the infarct was more frequent in males (68,31%) mainly associated to the smoking habit, Hypertension, and cholesterolemia in patients less than 74 years of age and in those patients aged 75 or more, the infarct was associated to Hypertension and Diabetes. The most affected side of the heart was the anterior part(44,6%), and the thrombolitic treatment was developd in an average of 211, 76 minutes. Deaths increased with age. The most significant variables associated to mortality in the infarcted patients were the fact of being hemodinamically classified into a Killip-Kimball (K-K) Grade III-IV and having had arrhythmia and cardiac rupture. Fundamento: Los grandes avances acaecidos en la medicina moderna en los últimos 30 a os , han impregnado al tratamiento del infarto agudo del miocadio un gran dinamismo y eficiencia, lo que permite hoy mostrar resultados alentadores, tanto en la disminución de la mortalidad como también en la mejoría de la calidad de vida del paciente. Objetivo: Precisar los resultados del tratamiento con estreptoquinasa recombinante, en ancianos y no ancianos con infarto agudo del miocadio. Métodos: Estudio prospectivo observacional de 325 pacientes ingresados con infarto agudo del miocardio en el Hospital Provincial Universitario ¨Dr. Gustavo Aldereguìa Lima¨, de Cienfuegos, que recibieron terapéutica trombolítica con estreptoquinasa recombinante ( Heberquinasa) a la dosis de 1 500 000 unidades, y tratamiento conjunto con 325 mg de ácido acetilsalicìlico. Resultados: La presencia de infarto fue más frecuente en el sexo masculino (68,31 %); asociado en mayor porcentaje al tabaquismo, la hipertensión arterial, la hipercolesteronemia en los pacientes menores de 74 a os ; la hipertensión arterial y la diabetes en los mayores de 75 a os; la cara